IontoPatch

What IontoPatch does

IontoPatch is a private medical device company headquartered at 1685 Marthaler Lane, St. Paul, Minnesota, that designs and manufactures disposable, single-use iontophoretic patches for transdermal drug delivery. The company's product line consists of three variants—IontoPatch STAT (4-hour wear, 80 mA/min), IontoPatch 80 (14-hour wear, 80 mA/min, designed for sensitive skin), and IontoPatch Extra Strength (8-hour wear, 120 mA/min)—each built on a self-contained battery architecture with proprietary zinc and silver chloride electrode coatings that generate a bipolar electric field to propel medication across intact skin into underlying tissue. IontoPatch is the only FDA 510(k) cleared iontophoretic patch on the market, classified as a Class 2 medical device and billable under CPT code 97033.

The company targets sports and orthopedic physicians, physiatrists, physical therapists, and athletic trainers for the treatment of near-surface musculoskeletal conditions including lateral epicondylitis, plantar fasciitis, patellar tendinitis, Achilles tendinitis, and rotator cuff tendinitis. Its go-to-market combines direct clinician sales, a vetted global distributor network, and a patient-facing channel through which patients can request prescriptions via downloadable medical-necessity forms. With over 60 million patches cumulatively administered across its installed base, IontoPatch holds an established presence in the clinical iontophoresis market. Pricing is not publicly disclosed, and the source material contains no data on revenue, funding history, ownership, management team, or M&A activity, leaving the company's financial profile opaque.

Name

IontoPatch

Legal name

IontoPatch

Website

https://iontopatch.com

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Short description

IontoPatch is a private St. Paul, Minnesota-based medical device manufacturer producing the only FDA 510(k) cleared disposable iontophoretic patches for transdermal drug delivery, serving sports medicine clinicians, physical therapists, and musculoskeletal patients via direct sales and a global distributor network.

Ownership category

akta.pro rank

Product category

Iontophoresis Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro industry

PRIMARYHLAHANAG

Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables

SECONDARYHLAHAIAE

Wearable Injectors & On-Body Delivery Systems

Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

• Iontophoresis patches
• Transdermal drug delivery
• Medical device therapy
• Musculoskeletal pain relief
• FDA cleared patches

Headquarters

HQ city

West Saint Paul

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Medical Device Sales: IontoPatch generates revenue through the sale of disposable single-use iontophoretic patches to clinicians, healthcare providers, and patients. The products are sold through a distributor network and directly to clinicians and patients. As an FDA 510(k) cleared Class 2 medical device, it is billable under CPT code 97033.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

IontoPatch manufactures and sells disposable, single-use iontophoretic transdermal drug delivery patches that use a self-contained battery-powered bipolar electric field to propel medication across intact skin into underlying tissue. The line includes three FDA 510(k) cleared variants (STAT, 80, Extra Strength) designed to treat near-surface musculoskeletal conditions (tennis elbow, plantar fasciitis, patellar tendinitis, Achilles tendinitis, rotator cuff tendinitis) as a pain-free, non-invasive alternative to needle injections. Products are sold to clinicians, distributed through a network of medical device distributors, and accessed by patients via prescription from licensed healthcare providers.

Product overview

IontoPatch is a line of three disposable, single-use iontophoretic transdermal drug delivery patches cleared by the FDA (510(k)). Each patch contains a self-contained battery and uses a low electric current to propel medication through intact skin into underlying tissue as an alternative to needle injections. The product line consists of three variants: IontoPatch STAT (fastest, 4-hour wear, 80 mA/min), IontoPatch 80 (lowest current for sensitive skin, 14-hour wear, 80 mA/min), and IontoPatch Extra Strength (highest dose, 8-hour wear, 120 mA/min). All three patches are wrap-able, compressible, and weight-bearing, designed to integrate into patients' lifestyles without interfering with daily activities.

Differentiator

Problem solved

Functional benefit

Brands

• IontoPatch STAT: Fastest treatment option with 4-hour average wear time and 80 mA/min dose strength. Best seller and most common patch recommended for patients new to iontophoresis.
• IontoPatch 80
• IontoPatch Extra Strength

Products and services

• IontoPatch STAT Fastest-acting IontoPatch variant with the shortest wear time at approximately 4 hours and an 80 mA/min dose strength; designed for patients seeking rapid pain relief and the most common patch recommended for those new to iontophoresis treatment of musculoskeletal conditions.
• IontoPatch 80 Lower-current IontoPatch variant designed for patients with sensitive or fair skin, featuring a flex-circuit battery design applied like an adhesive bandage; provides an 80 mA/min dose strength with a 1.3 ml fill volume and an average wear time of 14 hours.
• IontoPatch Extra Strength Highest-dose IontoPatch variant delivering 50% more drug per application compared to STAT or 80, with an 8-hour average wear time and a 120 mA/min dose strength; designed for patients requiring intensified pain management with more therapy in fewer treatments.

Quantifiable outcome

• Over 60 million patches clinically administered
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Noven Pharmaceuticals: Noven develops transdermal drug delivery patches and is a structural comparable as a wearable patch manufacturer serving pharmaceutical therapy markets.
• Chattem (Sanofi): Sanofi/Chattem markets topical pain and musculoskeletal therapies, representing a large incumbent competitor in the consumer and clinical pain relief categories IontoPatch also addresses.
• Hisamitsu Pharmaceutical: Hisamitsu (Salonpas) is a global leader in transdermal patches for pain relief, making it a comparable wearable drug delivery incumbent in adjacent indications to IontoPatch's musculoskeletal focus.
• 3M Drug Delivery Systems: 3M's Drug Delivery Systems division supplies transdermal patch technologies to pharmaceutical partners, making it a broad incumbent comparable in the wearable drug delivery platform category.

Emerging players

• ActivaTek: ActivaTek produces iontophoresis and electrotherapy devices for clinical and rehabilitation use, making it a smaller-scale comparator in the iontophoretic and electrotherapeutic device category.
• BioElectronics Corporation: BioElectronics markets wearable electrotherapy patches for musculoskeletal pain and recovery, overlapping with IontoPatch's non-invasive, self-contained wearable device approach.
• Zynex: Zynex develops electrotherapy and pain management medical devices, sharing IontoPatch's use of controlled electrical energy for therapeutic musculoskeletal applications.

Direct peers

• Teikoku Pharma USA: Teikoku Pharma manufactures transdermal patches for pain and other indications, overlapping with IontoPatch on drug-device combination transdermal delivery to similar patient populations.
• Iomed: Iomed is a developer of iontophoretic drug delivery systems historically used for localized corticosteroid delivery, directly overlapping with IontoPatch's therapeutic focus and clinician base.
• Empi (DJO Global): DJO/Empi is a long-standing iontophoresis device manufacturer and the most direct historical competitor to IontoPatch in clinical transdermal drug delivery for musculoskeletal conditions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/iontopatch
• Facebookfacebook.com/IontoPatch
• LinkedInlinkedin.com/company/iontopatch

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IontoPatch